Kraus Al - 31 Aug 2021 Form 4 Insider Report for Cytosorbents Corp (CTSO)

Role: Director
Signature: /s/ Kathleen P. Bloch attorney-in-fact for Al Kraus
Issuer symbol: CTSO
Transactions as of: 31 Aug 2021
Net transactions value: -$21,091
Form type: 4
Filing time: 02 Sep 2021, 16:31:46 UTC
Next filing: 09 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTSO	Common Stock	Options Exercise	$16,500	+4,000	+3.2%	$4.12	129,046	31 Aug 2021	Direct
transaction	CTSO	Common Stock	Sale	$37,591	-4,000	-3.1%	$9.40	125,046	31 Aug 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTSO	Stock Option (right to buy)	Options Exercise	$0	-4,000	-100%	$0.000000^*	0	31 Aug 2021	Common Stock	4,000	$4.12	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Reflects the weighted average price of sales on August 31, 2021. The shares were sold in multiple transactions at prices ranging from $9.38 to $9.409, inclusive. The reporting person undertakes to provide to CytoSorbents Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
F2	Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person.

Content

Reflects the weighted average price of sales on August 31, 2021. The shares were sold in multiple transactions at prices ranging from $9.38 to $9.409, inclusive. The reporting person undertakes to provide to CytoSorbents Corporation (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Includes: (i) the following RSUs that will be settled into common stock upon vesting upon a "Change In Control" of the Company as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 55,000 RSUs granted on April 8, 2015, (b) 5,000 RSUs granted on June 7, 2016, (c) 6,000 RSUs granted on February 24, 2017 and (d) 3,300 RSUs granted on March 15, 2018; and (ii) 55,746 shares of common stock owned by the reporting person.